juzo dynamic class 1 (18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size i
18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size i blueberry (juzo uk ltd -
juzo dynamic class 1 (18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size ii
18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size ii blueberry (juzo uk ltd -
juzo dynamic class 1 (18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size iii
18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size iii blueberry (juzo uk ltd -
juzo dynamic class 1 (18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size iv
18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size iv blueberry (juzo uk ltd -
juzo dynamic class 1 (18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size v
18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size v blueberry (juzo uk ltd -
juzo dynamic class 1 (18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size vi
18-21mmhg) armsleeve with shoulder and strap max lymphoedema garment size vi blueberry (juzo uk ltd -
fludeoxyglucose f-18 injection
lantheus medical imaging, inc. - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 200 mci in 1 ml - fludeoxyglucose f 18 injection is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.
sodium fluoride f 18- sodium fluoride f-18 injection
houston cyclotron partners lp dba cyclotope - sodium fluoride f-18 (unii: 9l75099x6r) (fluoride ion f-18 - unii:4m4we5n2ge) - fluoride ion f-18 200 mci in 1 ml - pregnancy category c any radiopharmaceutical including sodium fluoride f 18 injection has a potential to cause fetal harm. the likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. animal reproductive and developmental toxicity studies have not been conducted with sodium fluoride f 18 injection. prior to the administration of sodium fluoride f 18 injection to women of childbearing potential, assess for presence of pregnancy. sodium fluoride f 18 injection should be given to a pregnant woman only if clearly needed. it is not known whether sodium fluoride f 18 injection is excreted into human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of sodium fluoride f 18 injection or not to administer sodium fluoride f 18 injection, taking into account the importance of the drug to the mother. the body of scientific inform
fludeoxyglucose f-18- fludeoxyglucose f-18 injection injection
university of north dakota - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 500 mci in 1 ml - fludeoxyglucose f 18 injection,usp is indicated in pet (positron emission tomography) for: 1. identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. fludeoxyglucose f 18 injection, usp is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. none known
sodium fluoride f 18- sodium fluoride f-18 injection
ucsf radiopharmaceutical facility - sodium fluoride f-18 (unii: 9l75099x6r) (fluoride ion f-18 - unii:4m4we5n2ge) - fluoride ion f-18 200 mci in 1 ml - sodium fluoride f 18 injection is indicated for diagnostic positron emission tomography (pet) imaging of bone to define areas of altered osteogenic activity. none. pregnancy category c any radiopharmaceutical including sodium fluoride f 18 injection has a potential to cause fetal harm. the likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. animal reproductive and developmental toxicity studies have not been conducted with sodium fluoride f 18 injection. prior to the administration of sodium fluoride f 18 injection to women of childbearing potential, assess for presence of pregnancy. sodium fluoride f 18 injection should be given to a pregnant woman only if clearly needed. it is not known whether sodium fluoride f 18 injection is excreted into human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of sodium fl